Bloomberg L.P.9d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...
FierceBiotech5d
Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects
Novo Nordisk’s cannabinoid CB1 receptor blocker ... that the molecule suffers from some of the same problems that held back CB1 blockers in the past. European authorities withdrew the approval ...
The Financial Express4d
Novo Nordisk to seek regulatory approval for obesity drug early 2026
The company is also grappling with competition from Eli Lilly. (Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug ...
The Motley Fool7d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...
AOL12d
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...
Reuters5d
Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the ...
Business Insider10d
NVO INVESTOR NOTICE: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
San Diego, California--(Newsfile Corp. - January 30, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSE: NVO) securities between November 2 ...
MedCity News5d
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...
Reuters4d
Wegovy maker Novo Nordisk says surging growth driving emissions higher
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...
India TV11d
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...
Business Insider4d
Novo Nordisk A/S Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Investors With Losses To Reach Out
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of 10(b ...
Yahoo Finance6d
Jim Cramer Expects Novo Nordisk A/S (NVO) To Forecast A Good 2025
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate ...